The Role of Substance P Within Traumatic Brain Injury and Implications for Therapy.


Journal

Journal of neurotrauma
ISSN: 1557-9042
Titre abrégé: J Neurotrauma
Pays: United States
ID NLM: 8811626

Informations de publication

Date de publication:
08 2023
Historique:
medline: 21 8 2023
pubmed: 3 5 2023
entrez: 3 5 2023
Statut: ppublish

Résumé

This review examines the role of the neuropeptide substance P within the neuroinflammation that follows traumatic brain injury. It examines it in reference to its preferential receptor, the neurokinin-1 receptor, and explores the evidence for antagonism of this receptor in traumatic brain injury with therapeutic intent. Expression of substance P increases following traumatic brain injury. Subsequent binding to the neurokinin-1 receptor results in neurogenic inflammation, a cause of deleterious secondary effects that include an increased intracranial pressure and poor clinical outcome. In several animal models of TBI, neurokinin-1 receptor antagonism has been shown to reduce brain edema and the resultant rise in intracranial pressure. A brief overview of the history of substance P is presented, alongside an exploration into the chemistry of the neuropeptide with a relevance to its functions within the central nervous system. This review summarizes the scientific and clinical rationale for substance P antagonism as a promising therapy for human TBI.

Identifiants

pubmed: 37132595
doi: 10.1089/neu.2022.0510
doi:

Substances chimiques

Substance P 33507-63-0
Receptors, Neurokinin-1 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1567-1583

Auteurs

Adam Safwat (A)

Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.

Adel Helmy (A)

Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.

Arun Gupta (A)

Neurosciences Critical Care Unit, Addenbrooke's Hospital, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH